- Report
- October 2024
- 194 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- May 2024
- 135 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Report
- July 2022
- 203 Pages
Global
From €6680EUR$7,150USD£5,651GBP
- Report
- January 2023
- 124 Pages
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 134 Pages
Africa, Middle East
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 146 Pages
North America
From €3223EUR$3,450USD£2,727GBP
- Report
- January 2023
- 153 Pages
Europe
From €3223EUR$3,450USD£2,727GBP
- Report
- October 2022
- 209 Pages
Global
From €4157EUR$4,450USD£3,517GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
Solifenacin is a medication used to treat overactive bladder, a condition characterized by urinary urgency, frequency, and incontinence. It is a muscarinic receptor antagonist, meaning it works by blocking the action of a certain chemical in the body that causes bladder contractions. Solifenacin is available in both oral and injectable forms, and is typically prescribed for those who have not responded to other treatments. It is also used to treat urinary retention, a condition in which the bladder does not empty completely.
Solifenacin is one of several drugs used to treat urological disorders, which include urinary incontinence, urinary tract infections, and kidney stones. Other drugs used to treat these conditions include anticholinergics, alpha-blockers, and 5-alpha reductase inhibitors.
The solifenacin market is highly competitive, with several companies offering generic and branded versions of the drug. Some of the companies in the market include Astellas Pharma, Allergan, Mylan, and Teva Pharmaceuticals. Show Less Read more